ArticleCurrent medical science2025
HNMT Promotes the Occurrence and Progression of Nasopharyngeal Carcinoma by Inhibiting the IFN/TXNIP/p53 Axis.
Article in Current medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- HNMT promotes the motility-associated structures of breast cancer cells through the PI3K/Akt signaling pathway to promote tumor progression.Histology and histopathology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveHistamine N-methyltransferase (HNMT) is involved primarily in histamine metabolism, but emerging evidence suggests its potential role in cancer progression. This study investigated the role of HNMT in nasopharyngeal carcinoma (NPC) and its impact on interferon (IFN) signaling, thioredoxin-interacting protein (TXNIP), and p53 tumor suppressor pathways.
methodsHNMT expression in NPC tissues and cell lines was analyzed via qPCR and Western blotting. Functional assays, including cell proliferation, migration, invasion, and apoptosis, were performed after HNMT knockdown or overexpression. Transcriptomic sequencing was used to identify differentially expressed genes (DEGs). In addition, we examined the relationship between HNMT and the IFN/TXNIP/p53 axis via rescue experiments in vitro and in vivo models via qPCR and Western blotting.
resultsHNMT knockdown reduced cell proliferation, migration, and invasion, and promoted apoptosis in NPC tissues and cell lines. TXNIP was the most significantly upregulated gene following HNMT knockdown. Inhibition of the IFN pathway reversed these effects, confirming the role of HNMT in downregulating the IFN/TXNIP/p53 pathway. An in vivo study revealed that HNMT overexpression correlated with reduced expression of TXNIP and p53 in NCG mice.
conclusionIn NPC, HNMT promotes tumor growth and progression by inhibiting the IFN/TXNIP/p53 axis. These findings suggest that targeting the HNMT axis or restoring its function could provide new therapeutic strategies for NPC.
Indexed as
Identifiers
40498422What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.